Reply - 04/11/20
Doi : 10.1016/j.jaci.2020.07.028
Daniel J. Jackson, MD a 
, William W. Busse, MD a, Alkis Togias, MD b, James E. Gern, MD a, Mathew C. Altman, MD c, d
, William W. Busse, MD a, Alkis Togias, MD b, James E. Gern, MD a, Mathew C. Altman, MD c, d a University of Wisconsin School of Medicine and Public Health, Madison, Wis
b The National Institute of Allergy and Infectious Diseases, Bethesda, Md
c Department of Medicine, University of Washington, Seattle, Wash
d Benaroya Research Institute, Systems Immunology Division, Seattle, Wash
Le texte complet de cet article est disponible en PDF.
| This study was funded by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (grant nos. UM1AI114271 and UM1AI109565). The coauthorship by A. Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH, or any other agency of the US government. |
|
| Disclosure of potential conflict of interest: D. J. Jackson reports grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/National Heart, Lung, and Blood Institute (NHLBI) and GlaxoSmithKline and personal fees for the Data Safety Monitoring Board from Pfizer and for consulting from Novartis, Sanofi-Regeneron, GlaxoSmithKline, Vifor Pharma, and Astra Zeneca. W. W. Busse reports grants from the NIH/NIAID/NHLBI, during the conduct of the study and personal fees from Novartis, Sandoz, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Teva, Elsevier, Arrowhead, resTORbio, Med Learning Group, Practicing Clinicians Exchange, Boston Scientific, and Medscape. J. E. Gern reports grants from the NIH, personal fees and stock options from Meissa Vaccines, Inc, personal fees from AstraZeneca and Ena Therapeutics, and a patent on methods for production of rhinoviruses. M. C. Altman reports personal fees for consulting from Regeneron. A. Togias reports no relevant conflicts of interest. |
© 2020
Publié par Elsevier Masson SAS.
Vol 146 - N° 5
P. 1214-1215 - novembre 2020 Retour au numéro
Article précédent
- COVID-19: Start with the nose
- Brian Lipworth, Rory Chan, Chris RuiWen Kuo
- Corrigenda
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?